Disseminated histoplasmosis in immunosuppressed patients with non-specific clinical manifestations: Case report
Histoplasmosis diseminada en paciente inmunosuprimido con manifestaciones clínicas poco específicas: reporte de caso

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.
Show authors biography
Histoplasma was first described by the American physician Samuel Darling in 1905. The doctor noted the formation of intracellular organisms in tissues, such as the lungs, in a Martinique patient during the Panama Canal's construction. Its name was given because of its similarity to the plasmodium that attacks the histiocyte. We present the case of a 37-year-old male patient from Puerto Santander (Norte de Santander, Colombia), hospitalized at the Erasmo Meoz University Hospital (Cúcuta, Norte de Santander, Colombia) for acute abdominal pain.
The invasive fiberoptic bronchoscopy study on the lung sample's KOH revealed yeast, prompting empirical treatment with itraconazole 200 mg every 8 hours for three days, followed by 200 mg every 12 hours for six weeks. The pathology report refers to intracellular blasts in lung and lymph node samples. A 3 mg/kg/day of liposomal amphotericin was administered for two weeks. The patient was kept under medical observation until her clinical improvement and subsequent hospital discharge.
Article visits 154 | PDF visits 27
Downloads
- Bonifaz Trujillo J, editor. Histoplasmosis. En: Micología médica básica. 5 ed. McGraw Hill; 2015. Disponible en: https://accessmedicina.mhmedical.com/content.aspx?bookid=1529§ionid=98867733
- Aidé MA. Chapter 4 Histoplasmosis. J Bras Pneumol. 2009 Nov;35(11):1145-51. English, Portuguese. doi: 10.1590/s1806-37132009001100013. PMID: 20011851
- Oladele RO, Ayanlowo OO, Richardson MD, Denning DW. Histoplasmosis in Africa: An emerging or a neglected disease? PLoS Negl Trop Dis. 2018 Jan 18;12(1). doi: 10.1371/journal.pntd.0006046. PMID: 29346384; PMCID: PMC5773084.
- Mittal J, Ponce MG, Gendlina I, Nosanchuk JD. Histoplasma Capsulatum: Mechanisms for Pathogenesis. Curr Top Microbiol Immunol. 2019;422:157-191. doi: 10.1007/82_2018_114. PMID: 30043340; PMCID: PMC7212190.
- Tobón ÁM. Protocolo de estudio y manejo de histoplasmosis. Infectio. 2012;16:126-128. doi: 10.1016/s0123-9392(12)70039-5
- Negroni R. Histoplasmosis en América Latina. Biomedica. 2011;31(3):301. doi: 10.7705/biomedica.v31i3.597
- Landaeta ME, Colella MT, Caldera J, Roselló A, Mata-Essayag S. Presentaciones atípicas de histoplasmosis. Amc Acta Médica Colombiana. 2015. doi: 10.36104/amc.2015.527
- Ordóñez Blanco IT, Garzón Herazo JR, Lasso Apráes JI, Cruz Ramírez V. Histoplasmosis pulmonar crónica en un adulto inmunocompetente. Rev Colomb Neumol. 2018;29(2):67-73. doi: 10.30789/rcneumologia.v29.n2.2017.269
- Scully MC, Baddley JW. Epidemiología de la histoplasmosis. Curr Fungal Infect Rep. 2018;12:51–58. doi: 10.1007/s12281-018-0309-x
- Linder KA, Kauffman CA. Histoplasmosis: Epidemiology, Diagnosis, and Clinical Manifestations. Curr Fungal Infect Rep. 2019;13:120-128. doi: 10.1007/s12281-019-00341-x
- Centers for Disease Control and Prevention. Histoplasmosis Statistics [Internet]. Disponible en: https://www.cdc.gov/histoplasmosis/php/statistics/index.html